Pascal Soriot

Pascal Soriot is the Chief Executive Officer of AstraZeneca, a British-Swedish multinational pharmaceutical and biotechnology company. He is currently newsworthy due to two primary factors: his substantial compensation and AstraZeneca's strategic investment decisions. Recent reports indicate that Soriot's pay rose to £17.7 million last year, a 6.4% increase, potentially making him the UK's highest-paid CEO. Simultaneously, AstraZeneca has announced plans to invest $15 billion (£11 billion) in China by 2030, focusing on expanding medicines manufacturing and research and development. This investment decision followed a period where the company appeared to scale back expansion plans within the UK. Soriot's leadership and AstraZeneca's investment strategies are significant due to the company's prominent role in the global pharmaceutical industry and its impact on healthcare and economic landscapes in both the UK and China.